欧洲多发性骨髓瘤患者从静脉注射达拉曲单抗转为静脉注射达拉曲单抗前后的感受、认知和体验描述：欧洲多发性骨髓瘤患者的混合方法横断面调查

IF 2 3区医学 Q2 MEDICINE, GENERAL & INTERNAL

Patient preference and adherence Pub Date : 2024-09-10 DOI:10.2147/ppa.s453920

Valeria Magarotto, Julien Thevenon, Kate Morgan, Silene ten Seldam, Wafae Iraqi, Xavier Guillaume, Marjorie Leclerc, Claire Graziani-Taugeron, Bleuenn Rault, Dahbia Horchi

{"title":"欧洲多发性骨髓瘤患者从静脉注射达拉曲单抗转为静脉注射达拉曲单抗前后的感受、认知和体验描述：欧洲多发性骨髓瘤患者的混合方法横断面调查","authors":"Valeria Magarotto, Julien Thevenon, Kate Morgan, Silene ten Seldam, Wafae Iraqi, Xavier Guillaume, Marjorie Leclerc, Claire Graziani-Taugeron, Bleuenn Rault, Dahbia Horchi","doi":"10.2147/ppa.s453920","DOIUrl":null,"url":null,"abstract":"Purpose: To provide real-world data on patient perceptions and experiences with subcutaneous (SC) versus intravenous (IV) daratumumab. Patients and Methods: This was a cross-sectional, mixed-method (qualitative/quantitative) survey conducted in France, Germany, Spain and the United Kingdom involving multiple myeloma (MM) patients who switched from IV to SC daratumumab in the last 12 months (qualitative phase) or 24 months (quantitative phase [26 months in the UK]) prior to enrollment in the study. Results: Nine patients (mean age 65 years) participated in the qualitative phase and 113 patients (mean age 65.1 years) in the quantitative phase. Qualitative study results provided insights for the quantitative study and highlighted the benefits of switching from daratumumab IV to daratumumab SC as an improvement and a satisfactory change in patients’ treatment journey. Quantitative survey showed that patients were significantly less anxious, stressed and nervous before SC injections than IV infusions (mean score: 1.3, 1.1, 1.4 versus 2.1, 2.0, 2.0 respectively, p< 0.001), and significantly more reassured, ready/well-prepared, usual self and relieved (mean score: 3.8, 4.3, 3.7, 3.6 versus 3.0, 3.6, 3.1, 3.0 respectively, p< 0.001). Immediately after SC first injection, 96.5% patients were feeling well or very well versus 77.9% immediately after IV first infusion (p< 0.001). 97.3% patients were satisfied with their SC treatment versus 89.4% for the IV injection (p< 0.001). Patients spent significantly less time in hospital for an SC injection of daratumumab than for an IV infusion, 1.5 hours and 5.0 hours respectively (p< 0.001). In the UK, the differences between the two administration forms were less visible, likely because of confounding factors including a longer time passed since the switch from the IV to the SC form and administration of the survey. Conclusion: In line with results from other studies, the SC form of daratumumab had less impact on patients’ emotional burden than the IV form. Keywords: multiple myeloma, daratumumab, mode of administration, patients’ emotional burden, mixed method ","PeriodicalId":19972,"journal":{"name":"Patient preference and adherence","volume":"22 1","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe\",\"authors\":\"Valeria Magarotto, Julien Thevenon, Kate Morgan, Silene ten Seldam, Wafae Iraqi, Xavier Guillaume, Marjorie Leclerc, Claire Graziani-Taugeron, Bleuenn Rault, Dahbia Horchi\",\"doi\":\"10.2147/ppa.s453920\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To provide real-world data on patient perceptions and experiences with subcutaneous (SC) versus intravenous (IV) daratumumab. Patients and Methods: This was a cross-sectional, mixed-method (qualitative/quantitative) survey conducted in France, Germany, Spain and the United Kingdom involving multiple myeloma (MM) patients who switched from IV to SC daratumumab in the last 12 months (qualitative phase) or 24 months (quantitative phase [26 months in the UK]) prior to enrollment in the study. Results: Nine patients (mean age 65 years) participated in the qualitative phase and 113 patients (mean age 65.1 years) in the quantitative phase. Qualitative study results provided insights for the quantitative study and highlighted the benefits of switching from daratumumab IV to daratumumab SC as an improvement and a satisfactory change in patients’ treatment journey. Quantitative survey showed that patients were significantly less anxious, stressed and nervous before SC injections than IV infusions (mean score: 1.3, 1.1, 1.4 versus 2.1, 2.0, 2.0 respectively, p< 0.001), and significantly more reassured, ready/well-prepared, usual self and relieved (mean score: 3.8, 4.3, 3.7, 3.6 versus 3.0, 3.6, 3.1, 3.0 respectively, p< 0.001). Immediately after SC first injection, 96.5% patients were feeling well or very well versus 77.9% immediately after IV first infusion (p< 0.001). 97.3% patients were satisfied with their SC treatment versus 89.4% for the IV injection (p< 0.001). Patients spent significantly less time in hospital for an SC injection of daratumumab than for an IV infusion, 1.5 hours and 5.0 hours respectively (p< 0.001). In the UK, the differences between the two administration forms were less visible, likely because of confounding factors including a longer time passed since the switch from the IV to the SC form and administration of the survey. Conclusion: In line with results from other studies, the SC form of daratumumab had less impact on patients’ emotional burden than the IV form. Keywords: multiple myeloma, daratumumab, mode of administration, patients’ emotional burden, mixed method \",\"PeriodicalId\":19972,\"journal\":{\"name\":\"Patient preference and adherence\",\"volume\":\"22 1\",\"pages\":\"\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Patient preference and adherence\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/ppa.s453920\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Patient preference and adherence","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/ppa.s453920","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

目的：提供患者对皮下注射（SC）达拉单抗与静脉注射（IV）达拉单抗的看法和体验的真实世界数据：这是一项在法国、德国、西班牙和英国进行的横断面混合方法（定性/定量）调查，涉及在加入研究前12个月（定性阶段）或24个月（定量阶段[英国为26个月]）内从静脉注射达拉单抗转为皮下注射达拉单抗的多发性骨髓瘤（MM）患者：9名患者（平均年龄65岁）参加了定性研究，113名患者（平均年龄65.1岁）参加了定量研究。定性研究结果为定量研究提供了启示，并强调了从daratumumab静脉滴注转为daratumumab SC治疗的益处，认为这是患者治疗过程中的一种改进和令人满意的改变。定量调查显示，与静脉注射相比，患者在SC注射前的焦虑、压力和紧张程度明显降低（平均得分：分别为1.3、1.1、1.4对2.1、2.0、2.0，p< 0.001），而安心、准备好/准备充分、通常的自我和放松程度明显提高（平均得分：分别为3.8、4.3、3.7、3.6对3.0、3.6、3.1、3.0，p< 0.001）。首次皮下注射后，96.5% 的患者感觉良好或非常好，而首次静脉注射后，77.9% 的患者感觉良好或非常好（p< 0.001）。97.3%的患者对皮下注射治疗感到满意，而静脉注射的满意度为 89.4%（p< 0.001）。患者在医院接受达拉单抗皮下注射的时间明显少于静脉输注，分别为1.5小时和5.0小时（p< 0.001）。在英国，两种给药形式之间的差异不太明显，这可能是由于从静脉输注转为皮下注射的时间较长以及进行调查等混杂因素造成的：关键词：多发性骨髓瘤；达拉单抗；给药方式；患者情绪负担；混合法

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe

Purpose: To provide real-world data on patient perceptions and experiences with subcutaneous (SC) versus intravenous (IV) daratumumab.
Patients and Methods: This was a cross-sectional, mixed-method (qualitative/quantitative) survey conducted in France, Germany, Spain and the United Kingdom involving multiple myeloma (MM) patients who switched from IV to SC daratumumab in the last 12 months (qualitative phase) or 24 months (quantitative phase [26 months in the UK]) prior to enrollment in the study.
Results: Nine patients (mean age 65 years) participated in the qualitative phase and 113 patients (mean age 65.1 years) in the quantitative phase. Qualitative study results provided insights for the quantitative study and highlighted the benefits of switching from daratumumab IV to daratumumab SC as an improvement and a satisfactory change in patients’ treatment journey. Quantitative survey showed that patients were significantly less anxious, stressed and nervous before SC injections than IV infusions (mean score: 1.3, 1.1, 1.4 versus 2.1, 2.0, 2.0 respectively, p< 0.001), and significantly more reassured, ready/well-prepared, usual self and relieved (mean score: 3.8, 4.3, 3.7, 3.6 versus 3.0, 3.6, 3.1, 3.0 respectively, p< 0.001). Immediately after SC first injection, 96.5% patients were feeling well or very well versus 77.9% immediately after IV first infusion (p< 0.001). 97.3% patients were satisfied with their SC treatment versus 89.4% for the IV injection (p< 0.001). Patients spent significantly less time in hospital for an SC injection of daratumumab than for an IV infusion, 1.5 hours and 5.0 hours respectively (p< 0.001). In the UK, the differences between the two administration forms were less visible, likely because of confounding factors including a longer time passed since the switch from the IV to the SC form and administration of the survey.
Conclusion: In line with results from other studies, the SC form of daratumumab had less impact on patients’ emotional burden than the IV form.

Keywords: multiple myeloma, daratumumab, mode of administration, patients’ emotional burden, mixed method

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Patient preference and adherence MEDICINE, GENERAL & INTERNAL-

CiteScore

3.60

自引率

4.50%

发文量

354

审稿时长

6-12 weeks

期刊介绍： Patient Preference and Adherence is an international, peer reviewed, open access journal that focuses on the growing importance of patient preference and adherence throughout the therapeutic continuum. The journal is characterized by the rapid reporting of reviews, original research, modeling and clinical studies across all therapeutic areas. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease states are major areas of interest for the journal. As of 1st April 2019, Patient Preference and Adherence will no longer consider meta-analyses for publication.